Corcept (CORT) delivered earnings and revenue surprises of 19.05% and 7.35%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
CORT earnings call for the period ending March 31, 2020.
As of late, it has definitely been a great time to be an investor in Corcept Therapeutics.
New Strong Buy Stocks for May 5th
Q1 2020 Corcept Therapeutics Inc Earnings Call
Corcept Therapeutics Incorporated (CORT), a commercial-stage company engaged in the discovery and development of drugs that treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of cortisol, today announced the publication of an abstract in the April-May supplemental issue of the Journal of the Endocrine Society (JES). The abstract describes the Phase 3 trial (entitled “GRADIENT”) of relacorilant in patients with Cushing’s syndrome caused by adrenal adenomas or hyperplasia. Corcept’s poster describing the trial had been accepted for presentation at the 2020 Annual Meeting of the Endocrine Society (ENDO), which has been cancelled.
AT&T; makes the list Continue reading...
Joseph Belanoff has been the CEO of Corcept Therapeutics Incorporated (NASDAQ:CORT) since 1999. This report will...
Corcept (CORT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
One stock that fits that bill is Corcept Therapeutics, which had its Relative Strength (RS) Rating upgraded from 77 to 85 Wednesday. Corcept Therapeutics is not currently offering a proper buying opportunity. Corcept Therapeutics saw both earnings and sales growth rise last quarter.
Corcept Therapeutics Incorporated (CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of cortisol, will present novel immuno-oncology data from the selective cortisol receptor modulator relacorilant at the 2020 American Society of Clinical Oncology Annual Meeting. “Patients with adrenal cancer often have tumors that produce cortisol, which may limit the efficacy of immune checkpoint inhibitors,” said Andreas Grauer, MD, Corcept’s Chief Medical Officer. “Our hypothesis is that administering a selective cortisol modulator in combination with an immunotherapeutic agent such as pembrolizumab will treat the symptoms of hypercortisolism and help pembrolizumab achieve its maximum effect.1 The data presented in this abstract have informed the design of our Phase 1b trial in which 20-patients with metastatic or unresectable adrenal tumors that produce cortisol will receive our selective cortisol modulator relacorilant in addition to pembrolizumab.”
Corcept Therapeutics Incorporated (NASDAQ:CORT) shareholders might be concerned after seeing the share price drop 23...
Corcept Therapeutics Inc. (NASDAQ: CORT) continues to make its investors happy. The Menlo Park, Calif., biotech company beat earnings estimates in its first-quarter report last week. While the effects of the COVID-19 pandemic have led some companies to forgo guidance, Corcept reaffirmed its revenue estimates of $355 million to $375 million for the year.
Hedge funds don't get the respect they used to get. Nowadays investors prefer passive funds over actively managed funds. One thing they don't realize is that 100% of the passive funds didn't see the coronavirus recession coming, but a lot of hedge funds did. Even we published an article near the end of February and […]
MENLO PARK, Calif., April 27, 2020 -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report first quarter financial results and provide a corporate.
Like a puppy chasing its tail, some new investors often chase 'the next big thing', even if that means buying 'story...
Corcept Therapeutics (CORT) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Does Corcept Therapeutics (CORT) have what it takes to be a top stock pick for momentum investors? Let's find out.
MENLO PARK, Calif. , May 04, 2020 -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat.
Corcept's (CORT) earnings and revenues beat estimates in the first quarter of 2020. Solid adoption of the company's Cushing's syndrome drug, Korlym, drives sales.